Universal gene‑edited CAR‑T therapies turn donor T cells into off‑the‑shelf cancer treatments, cutting delays and costs while ...

Chimeric antigen receptor (CAR) T-cell therapy-associated immune-related adverse events (CirAEs) were associated with a high ...

Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental immunotherapy that takes an ...

Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...

Trojan horse” approach may enable ‘antigen-independent’ therapy with potential to treat cancers not traditionally amenable to immunotherapy.

UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes ...

Early phase 1 data suggest that in vivo, off-the-shelf CAR T therapy may be feasible in multiple myeloma, offering the ...

Initial results as promising as those in lupus and other non-cancer diseases driven by B c ...

The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...

Treatment with nivolumab (Opdivo) had limited benefit in patients with multiple myeloma (MM) or non-Hodkin lymphoma (NHL) ...

Cipla partners with ImmunoAct to introduce India’s first CAR-T cell therapy in Africa, enhancing accessible cancer treatment ...

The Food and Drug Administration (FDA) has approved Breyanzi ® (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) ...